Community-aquired pneumonia on the background of coronaviral disease (COVID-19): principles of diagnostics and determination of risk factors of pathological process aggravation
Keywords:community-acquired pneumonia, viral pneumonia, coronavirus disease, COVID-19, diagnosis, risk factors of aggravation
AbstractThe diagnosis of community-acquired pneumonia (CAP) on the background of COVID-19 is especially actual due to the prevalence of this pathology and the possible aggravation of the pathological process. The aim of our study was to improve the principles of CAP diagnostics on the background of COVID-19 and to determine risk factors for aggravating of the pathological process. Patients with respiratory symptoms who were hospitalized with suspected COVID-19 were examined. General clinical research methods were carried out, determination of SARS-CoV-2 virus RNA by PCR method, computer tomography (CT) to identify the features of lung tissue damage was performed. The main observation group consisted of 37 patients (men – 19 (51.4%), average age – 61 (57; 69) years) with pneumonia on the background of confirmed COVID-19. According to the severity of coronavirus disease, all patients of the main group were divided into 3 subgroups: subgroup 1 included 17 people with moderate COVID-19, subgroup 2 – 13 people with severe COVID-19, subgroup 3 – 7 people with critical COVID- 19 course. The levels of markers of systemic inflammation (C-reactive protein (C-RP) and fibrinogen) were also determined. Since patients with COVID-19 of moderate severity (which is characterized by the presence of community-acquired viral pneumonia) belong to the risk group of severe and critical course, it is suggested to consider the following risk factors for aggravating the pathological process as: temperature over 38.5°C, heart rate over 90 per minute, respiratory rate over 20 per minute, SpO2 ≤ 93%; absolute lymphopenia (less than 0.9 G/L) and an increase in serum levels of C-RP more than 50 mg/L and fibrinogen more than 5 g/L.
Feschenko YuI, Belosludtseva KO, Golubovska OA, Gumenyuk MI, et al. [Adapted evidence-based clinical guideline "Nosocomial pneumonia in adults: etiology, pathogenesis, classification, diagnosis, antimicrobial therapy and prevention"]. Vidannya ofitsiine. Kyiv: Natsionalna akademiya medichnih nauk. 2019;94. Ukrainian.
[Order of the Ministry of Health of Ukraine dated 23.04.2020 No. 953 “Amendments to the Standards of Medical Care“ Coronavirus Disease (COVID19)”, approved by the order of the Ministry of Health of Ukraine dated March 28, 2020 No. 722]. (2020). Ukrainian.
Pertseva TO, Kireeva TV, Belosludtseva KO. [Etiological, clinical and pathological features of community-acquired pneumonia in the epidemic period]. Ukrainskyi pulmonologichnyi zhurnal. 2016;3:15-20. Ukrainian.
Pertseva TO, Kireeeva TV, Belosludtseva KO. [Clinical and immunological features of lower respiratory tract pathology in the epidemic period]. Medicni perspektivi. 2010;15(2):4-10. Ukrainian.
Pertseva TO, Konopkina LI. [Anamnestic and clinical-functional features of the course of chronic obstructive pulmonary disease depending on the nature and degree of microbial load of the lower respiratory tract]. Ukr. pulmonol. zhurn. 2009;2:26-30. Ukrainian.
Fetisov VS. [STATISTICA statistical data analysis package]. Nizhyn: NDU im. M. Gogolya; 2018. p. 114. Ukrainian.
Bikash R. Sahu, Raj Kishor Kampa, Archana Padhi, Aditya K. Pandad. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta. 2020;509:91-94. doi: https://doi.org/10.1016/j.cca.2020.06.013
Heng Li, Shang-Ming Liua, Xiao-Hua Yub, Shi-Lin Tanga, et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. International Journal of Antimicrobial Agents. 2020;55(5). doi: https://doi.org/10.1016/j.ijantimicag.2020.105951
Coronavirus disease (COVID-19) Weekly Epidemiological Update of World Health Organization. [Internet]; 2020 [cited 2020 Aug 20]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6d49a76_4
Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. Journal of Investigative Medicine. 2018;66:957-65. doi: http://dx.doi.org/10.1136/jim-2018-000712
Joshua P. Metlay, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia: An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-67. doi: https://doi.org/10.1164/rccm.201908-1581ST
Dustin R Stamm, Holly A Stankewicz. Atypical Bacterial Pneumonia. StatPearls. [Internet]. 2020. Available from:
Goldblatt D, Miller E. Pneumococcal pneumonia. Thorax. 2020;75(1):6-7. doi: https://doi.org/10.1136/thoraxjnl-2019-214135
Joshua P Metlay, Grant W Waterer. Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Ideas and Opinions. 2020;7. doi: https://doi.org/10.7326/M20-2189
Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. Int J Mol Sci. 2016;17(12):2120. doi: https://doi.org/10.3390/ijms17122120
Nazario B. Coronavirus and Pneumonia. WebMD Medical Reference. [Internet]; 2020 [cited 2020 Aug 21]. Available from: https://www.webmd.com/lung/covid-and-pneumonia#1
Official Statistic in Coronavirus: Reported Cases and Deaths by Country, Territory, or Conveyance; 2020 [cited 2020 Aug 21].
Rong-Hui Du, Li-Rong Liang, Cheng-Qing Yang, Wen Wang, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524. doi: https://doi.org/10.1183/13993003.00524-2020
Raghu G, Wilson K. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. The Lancet. [Internet]. 2020. doi: https://doi.org/10.1016/S2213-2600(20)30349-0
How to Cite
Copyright (c) 2020 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.